Carney-Gersten P, Moore M D, Giuffre M
Oncol Nurs Forum. 1990 May-Jun;17(3):403-7.
Though therapeutic advances have been made in the treatment of ovarian carcinoma, success at achieving a cure in women with advanced disease has been elusive. Since advanced ovarian carcinoma is frequently confined to the peritoneum, the use of intraperitoneal (IP) chemotherapy is being studied. Dose-limiting toxicity and extended nausea and vomiting associated with intraperitoneal chemotherapy are problems with several of the drugs under study. The most beneficial drug for intraperitoneal use would be one that offers the maximum pharmacologic value without toxicity. An investigation at the Dartmouth-Hitchcock Medical Center in New Hampshire is exploring the use of alpha interferon in treating advanced ovarian carcinoma. This case report describes an individual's course of treatment and the challenges in managing the administration of the IP immunotherapy, anticipating problems, and identifying interventions necessary to achieving optimal patient comfort during this Phase I-II investigation.
尽管在卵巢癌治疗方面已取得了治疗进展，但对于晚期疾病女性患者而言，实现治愈仍难以捉摸。由于晚期卵巢癌常局限于腹膜，因此正在研究腹腔内（IP）化疗的应用。与腹腔内化疗相关的剂量限制性毒性以及持续性恶心和呕吐是正在研究的几种药物存在的问题。腹腔内使用的最有益药物应是一种能提供最大药理价值且无毒性的药物。新罕布什尔州达特茅斯-希区柯克医疗中心正在进行一项研究，探索使用α干扰素治疗晚期卵巢癌。本病例报告描述了一名患者的治疗过程以及在管理腹腔内免疫治疗给药、预测问题和确定在该I-II期研究期间实现患者最佳舒适度所需干预措施方面所面临的挑战。
